Core Viewpoint - Tianchen Medical (688013) has experienced a decline in stock price, closing at 42.8 yuan, down 4.89% from the previous week, with a current market capitalization of 3.473 billion yuan [1]. Performance Disclosure Highlights - Tianchen Medical forecasts a net profit of 73.74 million to 77.74 million yuan for the year 2025, excluding non-recurring gains and losses [1][3]. - The company expects a net profit attributable to shareholders of 82.89 million to 88.89 million yuan for 2025, indicating a year-on-year increase of 31 million to 37 million yuan, or a growth of 59.74% to 71.30% [1][3]. Company Announcement Summary - The anticipated growth in performance is primarily attributed to stable sales revenue from laparoscopic staplers and an increase in foreign exchange gains [1][3].

最新公告列表 《天臣医疗2025年年度业绩预告》 近日，天臣国际医疗科技股份有限公司披露《2025年年度业绩预告》。公告显示，公司预计2025年年度 实现归属于母公司所有者的净利润同比增加3,100.00万元到3,700.00万元，同比增长59.74%到71.30%； 扣除非经常性损益后的净利润同比增加2,700.00万元到3,100.00万元，增长57.77%到66.32%。业绩增长 主要得益于腔镜吻合器类产品销售收入稳定增长及汇兑收益增加。本次业绩预告未经注册会计师审计， 具体数据以正式披露的2025年年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月30日收盘，天臣医疗（688013）报收于42.8元，较前一交易日上涨1.18%，最新总市值为 34.73亿元。该股当日开盘42.08元，最高43.06元，最低41.8元，成交额达4982.63万元，换手率为 1.45%。 ...

Core Viewpoint - Tianchen Medical (688013.SH) expects a significant increase in net profit for the year 2025, projecting a rise of 31 million to 37 million yuan, which translates to a year-on-year increase of 59.74% to 71.30% [1] Financial Performance - The company anticipates that the net profit attributable to the parent company, excluding non-recurring gains and losses, will increase by 27 million to 31 million yuan, reflecting a year-on-year growth of 57.77% to 66.32% [1] Strategic Initiatives - The company continues to adhere to an innovation-driven strategy, enhancing both domestic and international operations, and consistently providing a rich product matrix to customers [1] Product Sales - Sales revenue from the company's endoscopic stapler products has shown stable growth during the reporting period [1] Currency Impact - The company experienced an increase in foreign exchange gains due to currency fluctuations affecting its foreign currency monetary items [1]

每经AI快讯，天臣医疗1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 与上年同期相比，将增加3100万元~3700万元，同比增加59.74%~71.3%。业绩变动主要原因是，报告期 内，公司坚持创新驱动战略，强化国内、外双轮驱动，持续为国内外客户提供丰富的产品矩阵，报告期 内腔镜吻合器类产品销售收入持续稳定增长。报告期内，由于汇率波动，导致公司持有外币货币性项目 产生的汇兑收益同比增加。 （记者 王晓波） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

天臣医疗公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比，将增加3100万元到 3700万元，同比增加59.74%到71.30%。预计2025年年度实现归属于母公司所有者的扣除非经常性损益 的净利润与上年同期相比，将增加2700万元到3100万元，同比增加57.77%到66.32%。报告期内，公司 坚持创新驱动战略，强化国内、外双轮驱动，持续为国内外客户提供丰富的产品矩阵，报告期内腔镜吻 合器类产品销售收入持续稳定增长。报告期内，由于汇率波动，导致公司持有外币货币性项目产生的汇 兑收益同比增加。 ...